Urotensin II and atherosclerosis

Peptides

Volumn 29, Issue 5, 2008, Pages 778-782

  Loirand, Gervaise ^a,b,c   Rolli Derkinderen, Malvyne ^a,b   Pacaud, Pierre ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c L INSTITUT DU THORAX   (France)

Author keywords

Artery; Atherosclerosis; Urotensin II; Urotensin receptor

Indexed keywords

MATRIX METALLOPROTEINASE; NEUROPEPTIDE RECEPTOR; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; CELL INFILTRATION; CELL PROLIFERATION; CHEMOTAXIS; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; ATHEROSCLEROSIS; CELL PROLIFERATION; CHEMOTACTIC FACTORS; ENDOTHELIAL CELLS; FOAM CELLS; HUMANS; INFLAMMATION; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS;

ANIMALIA;

EID: 42149166623     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.08.024     Document Type: Review

References (40)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Behm D.J., Harrison S.M., Ao Z., Maniscalco K., Pickering S.J., Grau E.V., et al. Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br J Pharmacol 139 (2003) 464-472
3. Birker-Robaczewska M., Boukhadra C., Studer R., Mueller C., Binkert C., and Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 23 (2003) 289-305
4. Bjorkbacka H., Kunjathoor V.V., Moore K.J., Koehn S., Ordija C.M., Lee M.A., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 10 (2004) 416-421
5. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
6. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
7. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
8. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 141-149
9. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
10. Djordjevic T., BelAiba R.S., Bonello S., Pfeilschifter J., Hess J., and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 519-525
11. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
12. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
13. Hassan G.S., Douglas S.A., Ohlstein E.H., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 (2005) 2464-2472
14. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
15. Katugampola S.D., Kuc R.E., Maguire J.J., and Davenport A.P. G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci (Lond) 103 48 (2002) 171S-175S
16. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
17. Loirand G., Guerin P., and Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 98 (2006) 322-334
18. MacLean M.R., Alexander D., Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130 (2000) 201-204
19. Maguire J.J., and Davenport A.P. Is urotensin-II the new endothelin?. Br J Pharmacol 137 (2002) 579-588
20. Maguire J.J., Kuc R.E., and Davenport A.P. Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131 (2000) 441-446
21. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 (2004) 1767-1774
22. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
23. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
24. Richards A.M., and Charles C. Urotensin II in the cardiovascular system. Peptides 25 (2004) 1795-1802
25. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
26. Russell F.D. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103 (2004) 223-243
27. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
28. Segain J.P., Rolli-Derkinderen M., Gervois N., Raingeard de la Bletiere D., Loirand G., and Pacaud P. Urotensin II is a New chemotactic factor for UT receptor-expressing monocytes. J Immunol 179 (2007) 901-909
29. Sheridan M.A., Plisetskaya E.M., Bern H.A., and Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66 (1987) 405-414
30. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
31. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
32. Tamura K., Okazaki M., Tamura M., Isozumi K., Tasaki H., and Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 72 (2003) 1049-1060
33. Thanassoulis G., Huyhn T., and Giaid A. Urotensin II and cardiovascular diseases. Peptides 25 (2004) 1789-1794
34. Wang H., Mehta J.L., Chen K., Zhang X., and Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol 44 (2004) 577-581
35. Wang Z.J., Ding W.H., Shi L.B., Bu D.F., Ren Z.W., and Tang C.S. Effects of oxidized-low density lipoprotein on expression of urotensin II receptor GPR14 in rat aortic smooth muscle cells. Zhonghua Yi Xue Za Zhi 86 (2006) 242-246
36. Wang Z.J., Shi L.B., Xiong Z.W., Zhang L.F., Meng L., Bu D.F., et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27 (2006) 858-863
37. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
38. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46 (2005) 738-744
39. Watanabe T., Takahashi K., Kanome T., Hongo S., Miyazaki A., Koba S., et al. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 29 (2006) 821-831
40. Witztum J.L., and Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 11 (2001) 93-102